Elite Pharmaceuticals Inc (ELTP)

[Couch]

You know i've been questioning the possibility of a RS vs the company doing a buy back. Obviously, I prefer the latter without the former. But has anyone considered the company may just do both?

No doubt 2014 is going to be a great year for Elite but the heavy pay off years are between 2015-17. IMO before anything like a RS is considered by the company....the company would want/need to be in the best possible position of strength and to do that the following are needed. 2015 at the earliest. Most companies associated with reverse splits are companies that lack a sound profitable business plan. As we know Elite has followed out its short and mid term business plan practically flawlessly.

1) Launch as many of those 12 generic products Nasrat brought with him from Actavis this year to become CFP off of operations and R&D costs related to Elite's ART. Isradipine alone should get us there by the end of 2014. In essence, Elite is becoming very close to CFP in its totality and garnering a profit off of its existing pipeline. The company already comes with a bad financial history. Many previous investors have been burnt on this stock. Show the investing community that you are already profitable before a split is even hinted at by the company. The company needs to increase its market cap considerably from here before the company considers a RS IMO.....and the number one way to do that is from the following:

2) The real question we are waiting on is how long before a BP/Actavis partnership shows itself? Does it take Elite officially garnering their third ART patent later this month? Show the investing community that you can monetize revenue from their patent estate. Elite owns several patents but when is the last time they've earned a dollar off of them??? Does Elite have to officially file their first 505b2 trial with the FDA and getting Fast Tracked Status? Does the partner want Elite to perhaps, additionally file their 505b1 trail for their signature Eli 216 ART opioid? If so, is Elite granted a Fast Track Status on this NDA and thus a rolling review? That would be key for Elite given is current financial struggles. The point is IMO Elite would want to partner with a BP if it is going to consider doing a RS. Reverse splits signal that a company isn't doing well one way or another and to counter this stigma Elite would need to show potential new investors why this isn't the case. A BP partner like Actavis would show this!

3) Show the existing ELTP longs that the company has created shareholder value that has stability over time. Say when the stock is able to hold a PPS above .30 for at least 6 months. The company no longer just needs to stay afloat financially. It needs to get to the Nasdaq. Very different reason to do a RS without the need for financial reasons alone! Show the investing community you have repeatable business cycles with exponential growth. We are doing that now but only in the last year. Make Doug Plassche show on several fronts he is lowering Elite's overall overhead costs.

*****How much of the investing community is barred from investing in Elite because it is on the OTC??? 85% most likely.

*****Still, though I understand Elite is beginning to be in a position where it would weather the bumpy storm of a RS.....I would prefer the company to monetize its ART products and then sell its Novel stake and authorize a stock buy back and not do a RS in the first place. However, you want to do a RS.....then show the existing shareholders you mean business by selling the Novel stake and buying back shares. You want me to sign a proxy vote for a RS. That just might make me sign it.

~~And it better come with one of these attached to it!

Our board of directors is submitting the Reverse Stock Split to our stockholders for approval with the primary intent of increasing the market price of our Common Stock to enhance our ability to meet the initial listing requirements of The NASDAQ Capital Market and to make our Common Stock more attractive to a broader range of institutional and other investors.